Abstract: PDL1-pHLIP, a preparation method of the PDL1-pHLIP, and an application of the PDL1-pHLIP in treatment of autoimmune diseases are provided. A fusion peptide is prepared by binding a pH low insertion peptide and an extracellular domain of PDL1. The pH low insertion peptide may be inserted onto a cell membrane of a focus tissue in an acid environment; the PDL1 bound to the pH low insertion peptide is subjected to targeting localization at the focus by utilizing the above properties of the pH low insertion peptide; a PD-1/PD-L1 negative signal of the focus tissue is enhanced by utilizing the pH low insertion peptide; and immune response of effector T cells is suppressed at the source, thereby achieving an effect of preventing and treating the autoimmune diseases.

Abstract: In a head pose estimation method, the method includes obtaining an image. The image includes a target face. Key point recognition processing is performed through a first network model based on the image. A two-dimensional key point coordinate set and a three-dimensional key point coordinate set of the target face are obtained. The first network model includes a first branch network that is configured to recognize the two-dimensional key point coordinate set and a second branch network that is configured to recognize the three-dimensional key point coordinate set. A head pose corresponding to the target face in the image is determined according to the two-dimensional key point coordinate set and the three-dimensional key point coordinate set.

Abstract: An improved pH low insertion peptide which is obtained by repeating the sequence of the extracellular domain of a pH low insertion peptide one or more times based on the sequence of the pH low insertion peptide already existing in the prior art. The pH low insertion peptide uses tumor cells cultured in vitro to prove that the improved pH low insertion peptide is targeted to the surface of tumor cells. Also disclosed are compositions composed of the pH low insertion peptide or the improved type thereof, and these compositions can be used for tumor treatment, diagnosis and identification. The experiments also find that the extracellular domain region of the pH low insertion peptide or the improved type thereof has antigenicity, and the immunized antibody can be used for tumor treatment. The above research results provide a basis for the development of tumor therapeutic drugs.

Abstract: PDL1-pHLIP, a preparation method of the PDL1-pHLIP, and an application of the PDL1-pHLIP in treatment of autoimmune diseases are provided. A fusion peptide is prepared by binding a pH low insertion peptide and an extracellular domain of PDL1. The pH low insertion peptide may be inserted onto a cell membrane of a focus tissue in an acid environment; the PDL1 bound to the pH low insertion peptide is subjected to targeting localization at the focus by utilizing the above properties of the pH low insertion peptide; a PD-1/PD-L1 negative signal of the focus tissue is enhanced by utilizing the pH low insertion peptide; and immune response of effector T cells is suppressed at the source, thereby achieving an effect of preventing and treating the autoimmune diseases.

Abstract: A pH low insertion peptide which is obtained by repeating the sequence of the extracellular domain of a pH low insertion peptide one or more times based on the sequence of the pH low insertion peptide already existing in the prior art. The present application uses tumor cells cultured in vitro to prove that the improved pH low insertion peptide is targeted to the surface of tumor cells; in addition, also disclosed is a compositions composed of the pH low insertion peptide or the improved type thereof, and these compositions can be used for tumor treatment, diagnosis and identification. The experiments of the present application also find that the extracellular domain region of the pH low insertion peptide or the improved type thereof has antigenicity, and the immunized antibody can be used for tumor treatment. The above research results provide a theoretical basis for the development of tumor therapeutic drugs.